| アブストラクト | BACKGROUND: Calcitonin gene-related peptide (CGRP) inhibitors have been FDA-approved for migraine prophylaxis and relief. However, their safety profile remains uncertain. This study analyzes adverse events (AEs) and signals of disproportionate reporting (SDRs) using the FDA Adverse Event Reporting System (FAERS). RESEARCH DESIGN AND METHODS: We analyzed FAERS reports from approval through Q2 2023, standardizing terms using preferred terminology and system organ class (SOCs) classifications. Disproportionality analyses (ROR, PRR, IC) identified SDRs and inclusion in FDA prescribing information was reviewed. Additional analyses included comparisons with other migraine drugs, indication-based sensitivity analyses and causality assessment using the Bradford Hill framework. RESULTS: Galcanezumab showed strong signals for underdose (ROR 47.4; 95% CI 43.79-51.3), alopecia (5.72; 5.09-6.43), and constipation (6.01; 5.35-6.75), while fremanezumab exhibited notable associations with alopecia (6.9; 5.72-8.33) and weight increased (6.34; 5.18-7.76). Among gepants, rimegepant was linked to somnolence (4.52; 3.57-5.73) and dizziness (3.73; 3.15-4.42) and atogepant showed a strong signal for therapy interruption (16.58; 12.86-21.38). CONCLUSIONS: This study highlights CGRP inhibitor-associated AEs, underscoring the need for clinical monitoring and risk identification. Early detection of AEs and SDRs can inform protective measures to enhance patient safety. |
|---|
| ジャーナル名 | Expert opinion on drug safety |
|---|
| Pubmed追加日 | 2025/4/22 |
|---|
| 投稿者 | Lee, Nai; Ok, Jihoon; Kwon, Yonghoon; Rhee, Su-Jin; Kim, Yun |
|---|
| 組織名 | College of Pharmacy, Daegu Catholic University, Gyeongsan, Gyeongsangbuk-do,;South Korea.;College of Pharmacy, Wonkwang University, Iksan, Jeollabuk-do, South Korea. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40261259/ |
|---|
